FDA’s Latest Peptide Warning Letters: What Five Companies Got Cited For
The FDA's July 2026 advisory committee vote on peptide compounding got most of the attention this year, but a quieter, more concrete story unfolded in parallel: the agency sending formal warning letters to specific online sellers. Five companies were cited together in the most recent round, and what they were actually selling is more revealing than the fact that letters were sent at all.
Key Takeaways
The FDA issued warning letters to five US-headquartered companies: Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations LLC (doing business as Tex Peptides), citing violations related to the sale of unapproved new drugs.
All five were selling unauthorized versions of retatrutide, Eli Lilly’s investigational obesity drug not approved anywhere in the world, and semaglutide, sold legitimately as Wegovy and Ozempic.
Several also sold copycat versions of drugs that are already FDA-approved: tesamorelin (approved as Egrifta), elamipretide (approved as Forzinity for Barth syndrome), and bremelanotide (approved as Vyleesi for hypoactive sexual desire disorder), meaning these weren’t only unapproved research compounds but unauthorized copies of existing prescription medications.
Every company labeled its products “for research purposes only” or “not for veterinary or human use,” but the FDA stated that evidence gathered directly from each website established the products were actually intended for human use, rejecting the labeling as a legal shield.
This enforcement action ran alongside, not against, the FDA’s separate 2026 advisory committee vote to ease compounding restrictions on other peptides, meaning the agency loosened one pathway for licensed pharmacies while simultaneously tightening enforcement against unlicensed retail sellers.
Which Companies Received Warning Letters, and For What?
The FDA sent warning letters to five US-headquartered sellers: Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations LLC, doing business as Tex Peptides. Each letter detailed violations tied to selling new drugs that remain unapproved by the FDA. The common thread across all five companies was retatrutide and semaglutide, sold as unauthorized copies of drugs that are either fully investigational (retatrutide) or already approved and tightly regulated when sold legitimately (semaglutide, as Wegovy and Ozempic).
Were These Copies of Unapproved Drugs, or Approved Ones Too?
Both, and that distinction matters more than it might seem. Selling an unauthorized version of retatrutide means selling a copy of a drug that has never been approved by any regulator anywhere. But several of the companies cited were also selling unauthorized copies of tesamorelin, sold legitimately as Egrifta and approved for a specific indication; elamipretide, approved as Forzinity for Barth syndrome; and bremelanotide, approved as Vyleesi for hypoactive sexual desire disorder. Copying an approved drug without going through the same manufacturing, prescribing, and pharmacy channels required for the real product is a different, and in some ways more direct, violation than selling an unapproved research compound, because a genuine, legal version of the same drug already exists through proper channels.
Why Doesn’t “Research Use Only” Protect These Sellers?
This labeling has come up repeatedly across coverage on this site, and this enforcement action shows exactly how the FDA treats it. Every company in this round labeled its products for research purposes only or not for human use. The FDA’s letters state directly that evidence gathered from each company’s own website, meaning product descriptions, dosing suggestions, and marketing language, established that the products were actually intended for human use regardless of the disclaimer. A label is not a legal shield if a company’s own marketing contradicts it.
What Risks Does the FDA Say These Products Actually Pose?
The FDA’s letters emphasize a specific, mechanical risk rather than a vague warning: injectable products that haven’t gone through FDA review can pose risks of serious harm because they enter the bloodstream directly, bypassing the body’s natural defenses against toxins and pathogens that oral products would have to pass through first. That’s a distinct and more immediate risk framing than the general contamination and mislabeling concerns covered elsewhere on this site, and it applies specifically to the injectable route these five companies were selling through.
Does This Contradict the FDA’s Other 2026 Peptide Actions?
Not as directly as it might first appear, but the two tracks are worth holding side by side. Earlier in 2026, the FDA’s own Pharmacy Compounding Advisory Committee voted to recommend easing restrictions on several other peptides for licensed compounding pharmacies, a process covered in detail elsewhere on this site. That vote and this enforcement action are aimed at different parts of the supply chain: one is about whether state-licensed, regulated compounding pharmacies may eventually prepare certain peptides under specific conditions; the other is about unlicensed retail websites selling directly to consumers with no prescription, no pharmacy oversight, and no regulatory review at all. The FDA can genuinely be loosening one pathway while tightening enforcement against the other, because they are not the same pathway.
The Bottom Line
Five companies received formal warning letters for selling unauthorized copies of both unapproved investigational drugs and, in several cases, drugs that are already FDA-approved and available through legitimate channels. The “research use only” labeling that underpins most of the online peptide market did not protect any of them, because the FDA looked past the label to the companies’ own marketing. This is a concrete, current example of the gap between what a disclaimer claims and what enforcement actually turns on.
Comments